VIVUS
VIVUS is a pharmaceutical company dedicated to addressing serious medical conditions and life-limiting diseases, with a diverse portfolio including PANCREAZE® for Exocrine Pancreatic Insufficiency and QSYMIA® for chronic weight management.
Overview of VIVUS
VIVUS is a company dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. With a growing portfolio of products, VIVUS focuses on developing high-potential molecules with compelling safety and efficacy potential. The company has a global footprint with locations in the United States, Netherlands, Switzerland, and Canada.
Products
VIVUS has a varied portfolio of products aimed at different therapeutic areas. PANCREAZE® is used for managing Exocrine Pancreatic Insufficiency (EPI) through pancreatic enzyme replacement therapy. QSYMIA® (phentermine and topiramate extended-release capsules) is an oral weight management medication indicated for both adults and pediatric patients. QSIVA® is a weight management product approved in several European countries. PANCREAZE® MT is available in Canada for treating pancreatic insufficiency.
Key Collaborations and Milestones
VIVUS announced a notable collaboration with UpScriptHealth on April 22, 2024, enhancing its reach in providing therapeutic solutions. Some of the significant milestones include the approval of MUSE® in 1997, the launch of QSYMIA® in 2012, and the acquisition of PANCREAZE® in 2018. These milestones reflect VIVUS’s commitment to advancing medical therapies and innovation.
Research and Development
VIVUS is actively engaged in developing new therapies and enhancing its product pipeline. VI-0106 is a lead pipeline program being developed to treat pulmonary arterial hypertension (PAH). The company is also working on VI-0609 for bone marrow transplant preparation and VI-0809 and VI-0810 for diabetes. This R&D effort aims to transform high-potential molecules into effective proprietary products.
Clinical Data and Safety Programs
New clinical data has demonstrated that QSYMIA reduces blood pressure, further supporting its use in chronic weight management. VIVUS has implemented a Risk Evaluation and Mitigation Strategy (REMS) for QSYMIA to ensure patient safety. This strategy underscores the company’s commitment to delivering safe and effective treatments for chronic conditions.